To include your compound in the COVID-19 Resource Center, submit it here.

Neurex adds a late stage product

Neurex adds a late-stage product

Neurex Corp. was to announce today the acquisition of Creagen, a Boston-based company developing the thrombolytic agent Pro-Urokinase and Walk Through Mutagenesis technology for protein engineering.

NXCO will issue 1.95 million shares of common stock in exchange for all of the shares outstanding of Creagen, giving Creagen shareholders a

Read the full 547 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE